Skip to main content

Table 2 Characteristics of the patient cohort, and baseline information

From: Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm

Age mean (range), years

68.5 (32.5–91.5)

Gender

 Male n (%)

39 (72%)

 Female n (%)

15 (28%)

Primary nodular melanoma

 Yes n (%)

11 (20%)

 No n (%)

41 (76%)

 Undetermined n (%)

2 (4%)

Breslow thickness mean (range), mm

4.11 (0.37–28)

BRAF V600 status

 Wild type n (%)

33 (61%)

 Mutant n (%)

13 (24%)

 Undetermined n (%)

8 (15%)

Previous ipilimumab n (%)

22 (41%)

Previous nivolumab n (%)

0 (0%)

Baseline tumor size before pembrolizumab mean (range), mm

79 (5–247)

Follow-up period median (range), months

9 (2–35)